Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Up 0.5 %

Shares of NASDAQ CHEK opened at $2.22 on Thursday. The business has a fifty day simple moving average of $2.26 and a 200-day simple moving average of $2.49. The company has a market cap of $12.99 million, a price-to-earnings ratio of -0.74 and a beta of 0.45. Check-Cap has a 12 month low of $1.30 and a 12 month high of $4.63.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.